BOSTON, Mass., July 8, 2026
Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) has published the complete results from the company’s pivotal Phase 3 TRANSCEND clinical trial evaluating IMCIVREE® (setmelanotide) for the treatment of acquired hypothalamic obesity (HO). The publication represents an important scientific milestone for the company following the U.S. Food and Drug Administration (FDA) approval of IMCIVREE earlier this year as the first and only approved therapy for acquired hypothalamic obesity in adults and children aged four years and older. The TRANSCEND trial, recognized as the largest and longest placebo-controlled study ever conducted in this rare neuroendocrine disease, demonstrated statistically significant improvements in body mass index (BMI) reduction and hunger control, reinforcing the clinical value of targeting the melanocortin-4 receptor (MC4R) pathway. Publication in one of the world’s leading peer-reviewed medical journals further strengthens the evidence supporting IMCIVREE as a disease-targeted therapy for patients with limited treatment options.
Phase 3 Trial Demonstrated Significant Weight Loss and Hunger Reduction
The global Phase 3 TRANSCEND study enrolled patients aged four years and older with acquired hypothalamic obesity caused by hypothalamic injury. A total of 120 participants formed the primary analysis population after completing 52 weeks of treatment in a randomized, double-blind, placebo-controlled study. Patients receiving once-daily subcutaneous IMCIVREE achieved a 19.8% placebo-adjusted reduction in BMI, while the treatment group recorded a 16.5% mean BMI reduction from baseline compared with a 3.3% BMI increase among placebo-treated patients (p<0.0001). Importantly, 80% of patients treated with IMCIVREE achieved at least a 5% reduction in BMI, while participants also experienced clinically meaningful improvements in hunger, one of the most debilitating symptoms associated with hypothalamic obesity. The therapy maintained a favorable safety profile, with no new safety signals identified and adverse events leading to treatment discontinuation remaining comparable between the treatment and placebo groups, supporting the long-term tolerability of the therapy.
NEJM Publication Strengthens Global Clinical Evidence
The publication highlights the growing body of clinical evidence supporting IMCIVREE as a targeted therapy for a disease with substantial unmet medical need. According to senior author Dr. Christian Roth, patients living with acquired hypothalamic obesity often experience rapid and persistent weight gain that significantly impacts their health and quality of life, while effective therapeutic options have historically been unavailable. The TRANSCEND results demonstrate consistent reductions in body weight together with meaningful improvements in hunger, findings that investigators believe could transform the management of this rare condition. Rhythm Pharmaceuticals President and Chief Executive Officer Dr. David Meeker noted that publication in NEJM reflects both the scientific strength of the clinical program and the commitment of patients, investigators, and families who participated in the study. The company also emphasized that following FDA approval in March 2026, the European Medicines Agency (EMA) has recommended marketing authorization for IMCIVREE in acquired hypothalamic obesity, while regulatory review remains ongoing in Japan, supporting the company’s strategy to expand global patient access.
Advertisement
IMCIVREE Targets the Underlying Cause of Hypothalamic Obesity
Acquired hypothalamic obesity develops after damage to the hypothalamus resulting from conditions such as craniopharyngioma, astrocytoma, traumatic brain injury, stroke, or inflammatory disorders. Injury to this critical brain region disrupts signaling through the MC4R pathway, leading to uncontrolled hunger, reduced energy expenditure, and severe, persistent weight gain. Unlike conventional obesity therapies that primarily address symptoms, IMCIVREE directly targets the disrupted MC4R signaling pathway, addressing the underlying biology responsible for disease progression. Beyond acquired hypothalamic obesity, Rhythm Pharmaceuticals continues advancing a broader pipeline focused on rare neuroendocrine diseases, including additional clinical programs evaluating setmelanotide, investigational MC4R agonists bivamelagon and RM-718, and preclinical therapies for congenital hyperinsulinism. The publication of the TRANSCEND Phase 3 trial in NEJM further establishes IMCIVREE as a scientifically validated, targeted treatment that has the potential to improve long-term outcomes for patients living with this challenging rare disease while reinforcing Rhythm Pharmaceuticals’ leadership in precision therapies for rare endocrine disorders.
Source: Rhythm Pharmaceuticals press release
